Importance There exists a paucity of literature that summarizes the effective management of
cutaneous immune-related adverse events (cirAEs) in patients with cancer who are …

Introduction Cutaneous squamous cell carcinoma (CSCC) is the second most frequent
malignant skin cancer, with an increasing worldwide incidence. Cemiplimab is a human …

Simple Summary This article investigates the cutaneous adverse immune effects induced by
immune checkpoint inhibitors. These drugs target proteins expressed on cancer cells that …

Importance There is limited information on immune checkpoint inhibitor–induced bullous
pemphigoid (ICI-BP) in patients with cancer, with most existing studies being case reports or …

Importance De novo bullous pemphigoid (BP) is a rare immune-mediated adverse event
from immune checkpoint inhibitors (ICIs) that can necessitate permanent discontinuation of …

Background: The most common autoimmune blistering disease, bullous pemphigoid (BP),
shows an increased prevalence in psoriatic patients and oncologic patients undergoing …

Keratinocytic cancers (KCs), specifically cutaneous squamous cell and basal cell
carcinomas, can respond to topical, intralesional, or systemic immunotherapies, but …

Cutaneous immune-related adverse events encompass a spectrum of dermatological
manifestations, including lichenoid reactions, psoriasiform eruptions, eczematous dermatitis …

Background Pemphigus vulgaris (PV) is a rare and severe autoimmune blistering disorder
affecting the skin and mucous membranes, characterized by the production of …

Introduction Locally advanced cutaneous squamous cell carcinoma (lacSCC) is rare.
Approximately one-fourth of the cases are observed among immunocompromised patients …